NCT06114407View on ClinicalTrials.gov

Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib

PHASE2RecruitingINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

December 30, 2024

Conditions
Spondyloarthritis, Axial
Interventions
DRUG

Baricitinib 2mg

Participants of arm 'A' will be treated with tablet baricitinib 2 mg twice daily for 12 weeks

DRUG

Tofacitinib 5 mg

Participants of arm 'B' getting tablet tofacitinib 5 mg twice daily for 12 weeks will be taken as historical control arm from another study on the efficacy of tofacitinib in refractory axial spondyloarthritis

Trial Locations (1)

1000

RECRUITING

Bangabandhu Sheikh Mujib Medical University, Dhaka

Sponsors
All Listed Sponsors
collaborator

Healthcare Pharmaceuticals

INDUSTRY

lead

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

OTHER